|Bid||0.4001 x 1800|
|Ask||0.4098 x 2200|
|Day's Range||0.3870 - 0.4300|
|52 Week Range||0.3600 - 5.5300|
|Beta (5Y Monthly)||-0.34|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 02, 2022 - Mar 07, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.69|
Evofem Biosciences Inc (NASDAQ: EVFM) shares are trading higher after the Health Resources and Services Administration (HRSA) and the U.S. Department of Labor issued updated guidance related to contraceptive access. The new guidance specifies that most insurers and pharmacy benefit managers (PBMs) must provide coverage, with no out-of-pocket costs to women, for FDA-approved contraceptive products, like Phexxi, prescribed by healthcare providers. "We believe this is a huge step forward toward ens
Evofem Biosciences, Inc. (NASDAQ: EVFM) today commended the Health Resources and Services Administration (HRSA) and the U.S. Department of Labor on their separately-issued updated guidance related to contraceptive access.
Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that the Company will present and host one-on-one meetings at the H.C. Wainwright BioConnect Virtual Conference being held from January 10 – 13, 2022.